A Boston-based pharmaceutical company sought to leverage publicly available scRNA-seq data for identifying/validating gene targets for inflammatory disease in a specific cell type. They wanted to fast-track the target identification and validation process which would help them accelerate their drug discovery process.
This case study from Elucidata details how the pharmaceutical company partnered with Elucidata to accelerate their target discovery and validation pipeline for inflammatory disease, and how they utilized Elucidata’s high-quality curated single-cell RNA sequencing (scRNA-seq) datasets, data concierge services, and expertise in computational biology.
Offered Free by: Elucidata
See All Resources from: Elucidata